SHP-1/TYK2 INTERACTION AND ITS DEFECT IN FHLH DISEASE
SHP-1/TYK2 相互作用及其在 FHLH 疾病中的缺陷
基本信息
- 批准号:2736705
- 负责人:
- 金额:$ 13.64万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1998
- 资助国家:美国
- 起止时间:1998-12-08 至 2001-11-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
SHP-1 is an SH-2 domain containing-protein tyrosine phosphatase
expressed predominantly in hematopoietic cells. It is a pivotal
negative regulator of signaling as demonstrated by the association of
SHP-1 deficiency with the murine "motheaten" phenotype, characterized
by hyper responsiveness of the motheaten hematopoietic cells to a
variety of extracellular stimuli. We and others have shown that SHP-1
functions by associating such membrane receptors through binding of its
SH2 domains to specific phosphotyrosine sites in the receptor
cytoplasmic region and dephosphorylating key substrates, including the
Jak family kinases. Our recent studies demonstrate an intrinsic Jak-
binding activity at the N-terminus of the phosphatase and functions
independently of the phosphotyrosine binding capacities of the SHP-1 SH2
domains. It may allow SHP-1 recruited to the receptors to specifically
target the kinases for dephosphorylation without affecting other
phosphotyrosine molecules in the receptor complexes. Since it
specifically binds to all Jak family members, we hypothesize that a
conserved SHP-1 docking site exists in all Jak kinases and is required
for SHP-1 dephosphorylation of the kinases. Importantly, we found that
reduced SHP-1 interactions with the Jak family member Tyk2 are
associated with the genetically transmitted human luekemic disease
familial hemophagocytic lymphohistiocytosis (FHLH). Since SHP-1 appears
to be normal in these individuals and that the defect affect only SHP-1
interaction with Tyk2, we hypothesize that a defect in Tyk2 or cellular
factors specifically affecting Tyk2 causes reduced SHP- 1/Tyk2
interactions in FHLH and contribute to the pathogenesis of the disease.
We propose to 1) define the region in Tyk2 that interacts with SHP-1 and
characterize its role in SHP-1 dephosphorylation of the kinase; 2)
characterize the molecular defect that causes reduced SHP-l/Tyk2
interactions in FHLH. These studies will make significant contributions
toward achieving our long term objective of elucidating the
physiological roles of SHP-1 in hematopoietic cells and defining its
involvement of hematopoietic diseases.
SHP-1是一个含SH-2结构域的蛋白酪氨酸磷酸酶
主要在造血细胞中表达。它是一个关键的
信号的负调节因子,如联合
SHP-1缺乏症伴小鼠“Motheten”表型,特征为
由于母系造血细胞对一种
各种细胞外刺激。我们和其他人已经证明了SHP-1
通过结合其受体来结合这种膜受体的功能
受体中特定的磷酸酪氨酸位点的Sh2结构域
细胞质区域和去磷酸化的关键底物,包括
杰克家族的血缘关系。我们最近的研究证明了一种内在的雅克-
磷酸酶N末端的结合活性及其功能
不依赖于SHP-1 SH2的磷酸酪氨酸结合能力
域名。它可能允许招募到受体的SHP-1特异性地
靶向去磷酸化的激酶而不影响其他
受体复合体中的磷酸酪氨酸分子。因为它
明确绑定到所有Jak家族成员,我们假设一个
保守的SHP-1对接位点存在于所有JAK激酶中,是必需的
用于SHP-1去磷酸化的激酶。重要的是,我们发现
减少了SHP-1与JAK家族成员TYK2的相互作用
与通过基因传播的人类狼疮有关
家族性噬血细胞淋巴组织细胞增多症(FHLH)。自从SHP-1出现以来
在这些个体中是正常的,并且缺陷只影响SHP-1
与TYK2的相互作用,我们假设TYK2或细胞中的缺陷
特定影响TYK2的因素导致SHP-1/TYK2降低
FHLH中的相互作用,并在疾病的发病机制中起作用。
我们建议1)定义TYK2中与SHP-1相互作用的区域,并
鉴定其在SHP-1去磷酸化该激酶中的作用;2)
表征导致SHP-L/TYK2降低的分子缺陷
FHLH中的相互作用。这些研究将做出重大贡献。
为了达到我们的长期目标,即澄清
SHP-1在造血细胞中的生理作用及其定位
血液病的累及。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Taolin Yi其他文献
Taolin Yi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Taolin Yi', 18)}}的其他基金
Anti-Cancer Activities of PTPase Inhibitors
PTPase 抑制剂的抗癌活性
- 批准号:
7054727 - 财政年份:2003
- 资助金额:
$ 13.64万 - 项目类别:
Anti-Cancer Activities of PTPase Inhibitors
PTPase 抑制剂的抗癌活性
- 批准号:
6892827 - 财政年份:2003
- 资助金额:
$ 13.64万 - 项目类别:
Anti-Cancer Activities of PTPase Inhibitors
PTPase 抑制剂的抗癌活性
- 批准号:
7226017 - 财政年份:2003
- 资助金额:
$ 13.64万 - 项目类别:
Anti-Cancer Activities of PTPase Inhibitors
PTPase 抑制剂的抗癌活性
- 批准号:
6609595 - 财政年份:2003
- 资助金额:
$ 13.64万 - 项目类别:
Anti-Cancer Activities of PTPase Inhibitors
PTPase 抑制剂的抗癌活性
- 批准号:
6745187 - 财政年份:2003
- 资助金额:
$ 13.64万 - 项目类别:
SHP-1 REGULATION OF THE KU SIGNALING PATHWAY
SHP-1 对 KU 信号通路的调节
- 批准号:
6138712 - 财政年份:1999
- 资助金额:
$ 13.64万 - 项目类别:
SHP-1 REGULATION OF THE KU SIGNALING PATHWAY
SHP-1 对 KU 信号通路的调节
- 批准号:
6627286 - 财政年份:1999
- 资助金额:
$ 13.64万 - 项目类别:
相似海外基金
Collaborative Research: Beyond the Single-Atom Paradigm: A Priori Design of Dual-Atom Alloy Active Sites for Efficient and Selective Chemical Conversions
合作研究:超越单原子范式:双原子合金活性位点的先验设计,用于高效和选择性化学转化
- 批准号:
2334970 - 财政年份:2024
- 资助金额:
$ 13.64万 - 项目类别:
Standard Grant
NSF-BSF: Towards a Molecular Understanding of Dynamic Active Sites in Advanced Alkaline Water Oxidation Catalysts
NSF-BSF:高级碱性水氧化催化剂动态活性位点的分子理解
- 批准号:
2400195 - 财政年份:2024
- 资助金额:
$ 13.64万 - 项目类别:
Standard Grant
Collaborative Research: Beyond the Single-Atom Paradigm: A Priori Design of Dual-Atom Alloy Active Sites for Efficient and Selective Chemical Conversions
合作研究:超越单原子范式:双原子合金活性位点的先验设计,用于高效和选择性化学转化
- 批准号:
2334969 - 财政年份:2024
- 资助金额:
$ 13.64万 - 项目类别:
Standard Grant
Mechanochemical synthesis of nanocarbon and design of active sites for oxygen reducton/evolution reactions
纳米碳的机械化学合成和氧还原/演化反应活性位点的设计
- 批准号:
23K04919 - 财政年份:2023
- 资助金额:
$ 13.64万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Creation of porous inorganic frameworks with controlled structure of metal active sites by the building block method.
通过积木法创建具有金属活性位点受控结构的多孔无机框架。
- 批准号:
22KJ2957 - 财政年份:2023
- 资助金额:
$ 13.64万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Catalysis of Juxaposed Active Sites Created in Nanospaces and Their Applications
纳米空间中并置活性位点的催化及其应用
- 批准号:
23K04494 - 财政年份:2023
- 资助金额:
$ 13.64万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Generation of carbon active sites by modifying the oxygen containing functional groups and structures of carbons for utilizing to various catalytic reactions.
通过修饰碳的含氧官能团和结构来产生碳活性位点,用于各种催化反应。
- 批准号:
23K13831 - 财政年份:2023
- 资助金额:
$ 13.64万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
CAREER: CAS: Understanding the Chemistry of Palladium and Silyl Compounds to Design Catalyst Active Sites
职业:CAS:了解钯和甲硅烷基化合物的化学性质以设计催化剂活性位点
- 批准号:
2238379 - 财政年份:2023
- 资助金额:
$ 13.64万 - 项目类别:
Continuing Grant
CAS: Collaborative Research: Tailoring the Distribution of Transient vs. Dynamic Active Sites in Solid-Acid Catalysts and Their Impacts on Chemical Conversions
CAS:合作研究:定制固体酸催化剂中瞬时活性位点与动态活性位点的分布及其对化学转化的影响
- 批准号:
2154399 - 财政年份:2022
- 资助金额:
$ 13.64万 - 项目类别:
Standard Grant
Engineering of Active Sites in Heterogeneous Catalysts for Sustainable Chemical and Fuel Production.
用于可持续化学和燃料生产的多相催化剂活性位点工程。
- 批准号:
RGPIN-2019-06633 - 财政年份:2022
- 资助金额:
$ 13.64万 - 项目类别:
Discovery Grants Program - Individual